Cadrenal Therapeutics, Inc. (CVKD) is a Ponte Vedra Beach, Florida-based late-stage biopharmaceutical company developing therapies for orphan cardiovascular and thrombo-inflammatory conditions. Its lead assets are tecarfarin, an oral vitamin K antagonist ready for Phase 3, CAD-1005, a 12-LOX inhibitor targeting heparin-induced thrombocytopenia, and frunexian, a factor XIa inhibitor. Shares were trading at $1.6073 just before midday on Wednesday, down $0.27, or 14.36%, from the prior session's close of $1.88. The direction is unambiguously lower, and it reverses part of Tuesday's one-day rally. No verified company-specific catalyst has surfaced for the decline; the move is consistent with profit-taking in an illiquid micro-cap whose shares had just jumped by a third in a single session.
No verified news or fundamental catalyst found on Wednesday explains the drop. The stock opened the session near $1.84 and slid to about $1.60 as sellers took control, with no fresh 8-K, press release, downgrade or data readout behind the selling. The most defensible assessment is that Tuesday's 34% gain attracted fast money that is now unwinding. That session lifted the stock from $1.40 to $1.88 on roughly 396,000 shares, about 3.5 times normal turnover, and pushed the relative strength index into the mid-70s, a zone that often precedes a pause. With a float of only about 3.2 million shares and a market capitalization near $5.7 million, order flow of a few hundred thousand shares is enough to move the tape by double digits. Tuesday's high of $1.92 now stands as the immediate resistance level, and the stock is still well above its 50-day moving average, near $1.10.
Underneath the technical reversal sits a verified fundamental overhang disclosed in the third-quarter report filed Monday evening. Cadrenal reported a net loss of $1.25 million, or $0.31 per share, for the quarter ended September 30, versus $2.69 million a year earlier, and held $3.06 million in cash at quarter-end, with about $2.7 million at the start of November. Management stated that current cash funds operations only into the first quarter of 2027 and repeated substantial doubt about the company's ability to continue as a going concern. The board has retained Tungsten Advisors to run a formal strategic process covering licensing, asset sales, partnerships and business combinations, with no deadline and no assurance of a transaction. With roughly 3.5 million warrants outstanding against 3.57 million shares, any equity-funded Phase 3 launch would be meaningfully dilutive — a structural reason rallies in this name tend to be sold.
Volume has been the story of the week. Tuesday's 396,150 shares far exceeded the roughly 111,000-share 20-day average, and by late morning Wednesday turnover was already approaching a typical full session's total. There was no scheduled sector event or macro release behind the reversal, and the selling was concentrated in this single name rather than reflecting a broad healthcare move. Technically, the stock remains roughly 10% above its 50-day average near $1.10 but about 55% below its 200-day average near $3.58, underscoring that the medium-term downtrend has not been broken. The 52-week range runs from $0.82 to $12.50 after a decline of more than 80% over the past year.
The score runs from 0, meaning no meaningful news and a move typical for the stock, to 100, meaning transformative news and an extreme, rare price move. This event earns 19 out of 100. No verified news was published on Wednesday, so the fundamental component is negligible; the material facts — the narrowed quarterly loss, going-concern language and strategic review — were already public before Tuesday's advance. The price move was about 2.6 times the stock's average absolute daily change of 5.53% over the past 60 sessions, and a swing of 14% or more occurred only three times in that window. Two weak components produce a low score.
Attention now shifts to the pace and substance of the Tungsten-led strategic review, which is the primary swing factor for the equity. Investors will look for signs of a partnership or asset transaction that could fund the CAD-1005 Phase 3 program without further equity issuance, and for any new shelf or warrant-related financing that would reset the share count. Cadrenal has not confirmed its next reporting date; consensus points to fourth-quarter results in the first quarter of 2027, with per-share losses expected to narrow again. Analyst coverage is thin, with two firms carrying bullish ratings. Risks include failure to reach a transaction, continued cash burn, Nasdaq listing compliance pressure, and the tendency of this thinly traded stock to swing by double digits on modest volume.
Tickeron maintains hundreds of AI trading bots spanning thousands of tickers, but the Trending AI Robots page narrows that universe to the strategies performing strongest under current market conditions. Bots differ by approach, holding period, performance metrics and the symbols they trade, so the curated list offers a practical starting point for comparing live results rather than theory. For readers tracking volatile names like this one, reviewing the trending lineup is a useful next step before committing capital to any single strategy.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
CVKD's Aroon Indicator triggered a bullish signal on November 16, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 113 similar instances where the Aroon Indicator showed a similar pattern. In 100 of the 113 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 88%.
The Momentum Indicator moved above the 0 level on November 03, 2026. You may want to consider a long position or call options on CVKD as a result. In 54 of 65 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.
CVKD moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for CVKD crossed bullishly above the 50-day moving average on November 10, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 7 of 10 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 70%.
Following a +4.86% 3-day Advance, the price is estimated to grow further. Considering data from situations where CVKD advanced for three days, in 146 of 181 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CVKD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
CVKD broke above its upper Bollinger Band on November 17, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 56 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.854) is normal, around the industry mean (3.592). P/E Ratio (-0.201) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (442.120).
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. CVKD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CVKD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology